Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
25 hedge funds and large institutions have $12.1M invested in Astria Therapeutics in 2017 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 2 reducing their positions, and 5 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 2
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
4% more funds holding
Funds holding: 24 → 25 (+1)
0.03% more ownership
Funds ownership: 0.55% → 0.59% (+0.03%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
24% less capital invested
Capital invested by funds: $15.8M → $12.1M (-$3.73M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$575K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$442K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$425K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$301K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$89.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
-$534K |
| 2 |
VF
Virtu Financial
New York
|
-$281K |
| 3 |
Millennium Management
New York
|
-$35K |
| 4 |
Jane Street
New York
|
-$25K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$16K |
ATXS Hedge Fund Activity: Q4 2017 in Review
25 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q4 2017, worth a combined $12.1M — down 24% from $15.8M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ATXS positions and 5 closed out — a net gain of 1 holder — while 12 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $575K. The largest seller was Wedbush Securities, exiting entirely with an estimated $534K sold.
- 25 institutional investors held Astria Therapeutics (ATXS) as of Q4 2017, up from 24 in Q3 2017.
- Funds reported $12.1M of Astria Therapeutics stock for Q4 2017, down 24% quarter-over-quarter.
- 6 funds opened new Astria Therapeutics positions in Q4 2017 and 5 closed out, a net change of +1 holder.
- The largest Astria Therapeutics buyer in Q4 2017 was Renaissance Technologies, an estimated $575K added.
- The largest Astria Therapeutics seller in Q4 2017 was Wedbush Securities, an estimated $534K sold.
Based on aggregated 13F filings for Q4 2017.